List of Noctiva drug patents
Noctiva is owned by Serenity Pharms Llc.
Noctiva contains Desmopressin Acetate.
Noctiva has a total of 5 drug patents out of which 0 drug patents have expired.
Noctiva was authorised for market use on 03 March, 2017.
Noctiva is available in spray, metered;nasal dosage forms.
Noctiva can be used as treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin, a method of treating nocturia due to nocturnal polyuria in adults.
The generics of Noctiva are possible to be released after 15 June, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7579321 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(3 months from now) | |
| US7405203 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(3 months from now) | |
| US7799761 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(1 year, 7 months from now) | |
| US9539302 | SERENITY PHARMS LLC | Safe desmopressin administration |
Jun, 2030
(7 years from now) | |
| US11419914 | SERENITY PHARMS LLC | Safe desmopressin administration |
Jun, 2030
(7 years from now) | |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: A method of treating nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin
Dosage: SPRAY, METERED;NASAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic